What is Herpes Zoster Ophthalmicus?
Herpes Zoster Ophthalmicus (HZO) is a viral infection caused by the varicella-zoster virus—the same virus responsible for chickenpox. After an initial infection (chickenpox), the virus remains dormant in the nerves and can reactivate years later as shingles (herpes zoster).
When the virus affects the ophthalmic branch of the trigeminal nerve, it leads to Herpes Zoster Ophthalmicus. This condition specifically involves the eye, eyelids, and surrounding forehead and scalp areas.
Side Effects of Herpes Zoster Ophthalmicus
The infection typically presents with symptoms such as severe eye pain, redness, swelling of the eyelid, and in some cases, a rash on the forehead and around the eye.
If left untreated or if the infection is severe, it can lead to serious complications including corneal ulcers, scarring, glaucoma, and even vision loss.
How is Herpes Zoster Ophthalmicus Diagnosed?
Diagnosis of Herpes Zoster Ophthalmicus is primarily based on clinical presentation and the patient's medical history. A healthcare provider will examine the affected eye and surrounding areas for characteristic symptoms like vesicular eruptions, along with assessing any associated eye complications.
In some cases, laboratory tests such as PCR (Polymerase Chain Reaction) may be performed to confirm the presence of the varicella-zoster virus.
Potential Treatment of Herpes Zoster Ophthalmicus
Early treatment is crucial to reduce the severity of symptoms and prevent complications. Antiviral medications such as acyclovir, valacyclovir, or famciclovir are commonly prescribed to combat the viral infection and shorten the duration of symptoms.
In addition to antiviral drugs, pain management and anti-inflammatory medications may be recommended to alleviate discomfort and reduce inflammation.
For cases involving severe eye complications, ophthalmic consultation and specific eye care treatments may be necessary to prevent long-term damage.
👉 Contact us for further information and receive a complimentary consultation.